NImmune Biopharma
Phase 3We develop novel immunoregulatory therapeutics for patients with autoimmune diseases, starting with ulcerative colitis and Crohn’s disease.
Market Cap
Private
Pipeline
—
Patents
—
Publications
—
Private Company
Total funding raised: $43M
About
We develop novel immunoregulatory therapeutics for patients with autoimmune diseases, starting with ulcerative colitis and Crohn’s disease.
Small Molecules
Funding History
2Total raised:$43M
Series A$35MOct 15, 2021
Seed$8MApr 15, 2019